$CNCL
CANCER CAPITAL CORP

2023 Q1 Form 10-K Financial Statement

#000155479523000097 Filed on March 30, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $5.699K $21.01K
YoY Change -37.44% 14.58%
Operating Profit -$5.699K -$21.01K
YoY Change -37.44% 14.58%
Interest Expense $2.606K $9.730K
YoY Change 19.21% 32.83%
% of Operating Profit
Other Income/Expense, Net -$5.709K -$21.46K
YoY Change 12.21% 16.26%
Pretax Income -$11.41K -$42.47K
YoY Change -19.65% 15.42%
Income Tax
% Of Pretax Income
Net Earnings -$11.41K -$42.47K
YoY Change -19.65% 15.42%
Net Earnings / Revenue
Basic Earnings Per Share -$0.01
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding 6.150M shares 6.150M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $17.86K $22.06K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $17.86K $22.06K
YoY Change 35472.58%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $17.86K $22.06K
Total Long-Term Assets $0.00 $0.00
Total Assets $17.86K $22.06K
YoY Change 35472.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $440.9K $433.7K
YoY Change 17.46%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $440.9K $433.7K
Total Long-Term Liabilities
Total Liabilities $440.9K $433.7K
YoY Change 17.46%
SHAREHOLDERS EQUITY
Retained Earnings -$476.2K -$464.8K
YoY Change 10.06%
Common Stock $6.150K $6.150K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$423.0K -$411.6K
YoY Change
Total Liabilities & Shareholders Equity $17.86K $22.06K
YoY Change 35472.58%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$11.41K -$42.47K
YoY Change -19.65% 15.42%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$4.199K -$15.01K
YoY Change -44.82% 21.65%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $37.00K
YoY Change 216.24%
NET CHANGE
Cash From Operating Activities -$4.199K -$15.01K
Cash From Investing Activities
Cash From Financing Activities $37.00K
Net Change In Cash -$4.199K $21.99K
YoY Change -3558.02%
FREE CASH FLOW
Cash From Operating Activities -$4.199K -$15.01K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2022Q2 dei Entity Public Float
EntityPublicFloat
0 usd
CY2021 us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
usd
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001130889
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2021 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
usd
CY2022 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2021 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2021 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2022Q4 us-gaap Capital
Capital
411599 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-464799 usd
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
000-32363
CY2022 dei Entity Registrant Name
EntityRegistrantName
CANCER CAPITAL CORP.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
WY
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
91-1803648
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
2157 S. Lincoln Street
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Salt Lake City
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
UT
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
84106
CY2022 dei City Area Code
CityAreaCode
801
CY2022 dei Local Phone Number
LocalPhoneNumber
323-2395
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
true
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6150000 shares
CY2022 dei Auditor Firm
AuditorFirmId
6117
CY2022 dei Auditor Name
AuditorName
Pinnacle Accountancy Group of Utah
CY2022 dei Auditor Location
AuditorLocation
Farmington, Utah
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22055 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
62 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
22055 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
62 usd
CY2022Q4 us-gaap Assets
Assets
22055 usd
CY2021Q4 us-gaap Assets
Assets
62 usd
CY2022Q4 CNCL Accounts Payable Related Parties Current1
AccountsPayableRelatedPartiesCurrent1
6000 usd
CY2021Q4 CNCL Accounts Payable Related Parties Current1
AccountsPayableRelatedPartiesCurrent1
6000 usd
CY2022Q4 CNCL Notes Payable Related Parties Classified Current1
NotesPayableRelatedPartiesClassifiedCurrent1
155125 usd
CY2021Q4 CNCL Notes Payable Related Parties Classified Current1
NotesPayableRelatedPartiesClassifiedCurrent1
145125 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
130275 usd
CY2021Q4 us-gaap Notes Payable Current
NotesPayableCurrent
97275 usd
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
77680 usd
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
65950 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
64574 usd
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
54844 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
433654 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
369194 usd
CY2022Q4 us-gaap Liabilities
Liabilities
433654 usd
CY2021Q4 us-gaap Liabilities
Liabilities
369194 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6150000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6150000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6150000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6150000 shares
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
6150 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
6150 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
47050 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
47050 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-464799 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-422332 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-411599 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-369132 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22055 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
62 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21008 usd
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18335 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
21008 usd
CY2021 us-gaap Operating Expenses
OperatingExpenses
18335 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-21008 usd
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-18335 usd
CY2022 CNCL Interest Expense Related Party1
InterestExpenseRelatedParty1
11729 usd
CY2021 CNCL Interest Expense Related Party1
InterestExpenseRelatedParty1
11132 usd
CY2022 us-gaap Interest Expense
InterestExpense
9730 usd
CY2021 us-gaap Interest Expense
InterestExpense
7325 usd
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-21459 usd
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-18457 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-42467 usd
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-36792 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-42467 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-36792 usd
CY2022 CNCL Earnings Per Share Basic And Diluted Cncl
EarningsPerShareBasicAndDilutedCNCL
-0.01
CY2021 CNCL Earnings Per Share Basic And Diluted Cncl
EarningsPerShareBasicAndDilutedCNCL
-0.01
CY2022 CNCL Weighted Average Number Of Shares Outstanding Basic And Diluted Cncl
WeightedAverageNumberOfSharesOutstandingBasicAndDilutedCNCL
6150000 shares
CY2021 CNCL Weighted Average Number Of Shares Outstanding Basic And Diluted Cncl
WeightedAverageNumberOfSharesOutstandingBasicAndDilutedCNCL
6150000 shares
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-332340 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-36792 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-369132 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-42467 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-411599 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-42467 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-36792 usd
CY2022 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
6000 usd
CY2021 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
6000 usd
CY2022 us-gaap Increase Decrease In Due To Other Related Parties
IncreaseDecreaseInDueToOtherRelatedParties
11730 usd
CY2021 us-gaap Increase Decrease In Due To Other Related Parties
IncreaseDecreaseInDueToOtherRelatedParties
11131 usd
CY2022 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
9730 usd
CY2021 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
7325 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15007 usd
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12336 usd
CY2022 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
33000 usd
CY2021 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
11700 usd
CY2022 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
4000 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
37000 usd
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11700 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
21993 usd
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-636 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
698 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22055 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62 usd
CY2022 CNCL Conversion Of Related Party Accounts Payable Into Note Payable Related Party
ConversionOfRelatedPartyAccountsPayableIntoNotePayableRelatedParty
6000 usd
CY2021 CNCL Conversion Of Related Party Accounts Payable Into Note Payable Related Party
ConversionOfRelatedPartyAccountsPayableIntoNotePayableRelatedParty
6000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-42467 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-36792 usd
CY2022 CNCL Weighted Average Number Of Share Outstanding Basic And Diluted Cncl
WeightedAverageNumberOfShareOutstandingBasicAndDilutedCNCL
6150000 shares
CY2021 CNCL Weighted Average Number Of Share Outstanding Basic And Diluted Cncl
WeightedAverageNumberOfShareOutstandingBasicAndDilutedCNCL
6150000 shares
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84C_eus-gaap--UseOfEstimates_zqX2zSFvfBVa" style="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="color: Black"><span id="xdx_86A_zf3wm7hzo0fg">d. Use of estimates</span></span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="color: Black"> </span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="color: Black">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p>
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84D_eus-gaap--ConcentrationRiskCreditRisk_zzDm4uSghVO5" style="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="color: Black"><span id="xdx_868_zr3nf7TNV4oj">e. Concentrations of Risk</span></span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="color: Black"> </span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="color: Black">As of December 31, 2022, two lenders represent in excess of <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20221231_zOs8S6I9ynoi">95</span>% of the Company’s Accounts Payable and Notes Payable for the fiscal years ended December 31, 2022 and 2021.</span></p>
CY2022 us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
0.95 pure
CY2022Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
464799 usd
CY2021Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
422332 usd
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
97608 usd
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
88690 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
97608 usd
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
88690 usd
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
8918 usd
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
7727 usd
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
8918 usd
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
7727 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
130275 usd
CY2021Q4 us-gaap Notes Payable Current
NotesPayableCurrent
97275 usd
CY2022 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.08 pure
CY2021 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.08 pure
CY2022 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
33000 usd
CY2021 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
11700 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
64574 usd
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
54844 usd
CY2022 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
6000 usd
CY2021 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
6000 usd
CY2022 CNCL Conversion Of Related Party Accounts Payable Into Note Payable Related Party
ConversionOfRelatedPartyAccountsPayableIntoNotePayableRelatedParty
6000 usd
CY2021 CNCL Conversion Of Related Party Accounts Payable Into Note Payable Related Party
ConversionOfRelatedPartyAccountsPayableIntoNotePayableRelatedParty
6000 usd
CY2022Q4 CNCL Notes Payable Related Parties Classified Current1
NotesPayableRelatedPartiesClassifiedCurrent1
155125 usd
CY2021Q4 CNCL Notes Payable Related Parties Classified Current1
NotesPayableRelatedPartiesClassifiedCurrent1
145125 usd
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
77680 usd
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
65950 usd
CY2022 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.08 pure
CY2021 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.08 pure

Files In Submission

Name View Source Status
0001554795-23-000097-index-headers.html Edgar Link pending
0001554795-23-000097-index.html Edgar Link pending
0001554795-23-000097.txt Edgar Link pending
0001554795-23-000097-xbrl.zip Edgar Link pending
cncl-20221231.xsd Edgar Link pending
cncl0328form10k.htm Edgar Link pending
cncl0328form10kexh31_1.htm Edgar Link pending
cncl0328form10kexh31_2.htm Edgar Link pending
cncl0328form10kexh32_1.htm Edgar Link pending
cncl-20221231_cal.xml Edgar Link unprocessable
cncl-20221231_def.xml Edgar Link unprocessable
cncl-20221231_lab.xml Edgar Link unprocessable
cncl-20221231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cncl0328form10k_htm.xml Edgar Link completed
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending